Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,796.50GBp
8:48am BST
Change (% chg)

28.00 (+0.59%)
Prev Close
4,768.50
Open
4,813.50
Day's High
4,816.00
Day's Low
4,772.50
Volume
245,715
Avg. Vol
2,533,426
52-wk High
5,585.07
52-wk Low
3,996.00

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.02
Market Cap(Mil.): £59,982.33
Shares Outstanding(Mil.): 1,265.90
Dividend: 68.90
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.16 16.22
EPS (TTM): -- -- --
ROI: -- 14.31 15.23
ROE: -- 15.64 13.84

France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS, Sept 15 French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.

15 Sep 2017

Aspen to buy remaining AstraZeneca anesthetic rights for up to $766 million

LONDON AstraZeneca said it had agreed to sell the remaining rights to a portfolio of anesthetics to South Africa's Aspen Group for up to $766 million, a year after Aspen bought the commercial rights outside the United States.

14 Sep 2017

CORRECTED-Aspen to buy remaining AstraZeneca anaesthetic rights for up to $766 mln

LONDON, Sept 14 AstraZeneca said it had agreed to sell the remaining rights to a portfolio of anaesthetics to South Africa's Aspen Group for up to $766 million, a year after Aspen bought the commercial rights outside the United States.

14 Sep 2017

Moderna, AstraZeneca heart drug succeeds early-stage trial

Biotech unicorn Modern Therapeutics said on Thursday its heart drug, developed along with British drugmaker AstraZeneca, met the main goal in an early-stage trial.

14 Sep 2017

Moderna, AstraZeneca heart drug succeeds early-stage trial

Sept 14 Biotech unicorn Modern Therapeutics said on Thursday its heart drug, developed along with British drugmaker AstraZeneca, met the main goal in an early-stage trial.

14 Sep 2017

UPDATE 2-Aspen Pharmacare shifts the needle to injectibles

JOHANNESBURG, Sept 14 South Africa's Aspen Pharmacare expanded its anaesthetic drugs portfolio with a $766 million deal with AstraZeneca as it focuses on injectibles rather than making tablets.

14 Sep 2017

Astra's Farxiga results may open up type 1 diabetes opportunity

FRANKFURT AstraZeneca's Farxiga was shown to help type-1 diabetics when added to standard insulin therapy, possibly opening up a additional market opportunity for the type-2 diabetes drug, the British drugmaker said in a statement on Thursday.

14 Sep 2017

Astra's Farxiga results may open up type 1 diabetes opportunity

FRANKFURT, Sept 14 AstraZeneca's Farxiga was shown to help type-1 diabetics when added to standard insulin therapy, possibly opening up a additional market opportunity for the type-2 diabetes drug, the British drugmaker said in a statement on Thursday.

14 Sep 2017

Aspen to buy remaining AstraZeneca anaesthetic rights for up to $766 million

LONDON AstraZeneca said on Thursday it had agreed to sell the U.S. rights to a portfolio of anaesthetics to South Africa's Aspen Group for up to $766 million (579.86 million pounds), a year after Aspen bought the rights outside the United States.

14 Sep 2017

South Africa's Aspen Pharmacare posts 46 pct profit jump

JOHANNESBURG, Sept 14 South Africa's Aspen Pharmacare reported a 46 percent rise in full-year profit, buoyed by a revenue boost from an anaesthetics portfolio acquired from AstraZeneca and GlaxoSmithKline, the company said on Thursday.

14 Sep 2017

Earnings vs. Estimates